Clinical potential of treatment with semaglutide in type 2 diabetes patients
Glucagon-like receptor agonists (GLP-1RAs) are included in current national and international guidelines as second-line treatment especially in patients with type 2 diabetes and concomitant cardiovascular disease (CVD). First-generation GLP-1RAs were two- or once-daily injectables, but longeracting...
Main Author: | Michael E Røder |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2019-12-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/clinical-potential-of-treatment-with-semaglutide-in-type-2-diabetes-patients/ |
Similar Items
-
Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
by: Hwi Seung Kim, et al.
Published: (2021-09-01) -
Semaglutide for the treatment of obesity
by: Rafał Oleszczuk, et al.
Published: (2022-01-01) -
The Discovery and Development of Liraglutide and Semaglutide
by: Lotte Bjerre Knudsen, et al.
Published: (2019-04-01) -
Glycemic treatment effect of oral semaglutide plus other antidiabetic medications: An Indian experience
by: Manoj Chawla, et al.
Published: (2022-01-01) -
Advances in GLP-1 treatment: focus on oral semaglutide
by: Freddy G. Eliaschewitz, et al.
Published: (2021-09-01)